@article{8f6a909b020b4c2da6e65ce58d37a5f8,
title = "Treatment Update in Systemic Lupus Erythematous",
keywords = "Anifrolumab, Belimumab, Euro-lupus, Lupus, Lupus low disease activity state, Lupus nephritis, Mycophenolate, Treatment target",
author = "Hoi, {Alberta Y.} and Morand, {Eric F.}",
note = "Funding Information: A.Y. Hoi has received research grants, consultancy fees, and honoraria from GSK, AstraZeneca, Merck Serono, UCB, and AbbVie. She was member of the Australian Benlysta Advisory Board in 2020, and is principal investigator for several phase 2 and 3 clinical trials in SLE. E.F. Morand has received research grants, consultancy fees, and honoraria from GSK, AstraZeneca, Merck Serono, UCB, Amgen, Eli Lilly, Biogen, Bristol Myers Squibb, and Janssen. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = jun,
day = "10",
doi = "10.1016/j.rdc.2021.04.012",
language = "English",
volume = "47",
pages = "513–530",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "Elsevier",
number = "3",
}